Comprehensive Genomic Profiling and Next Generation Functional Drug Screening for Patients With Aggressive Haematological Malignancies

Launched by MEDICAL UNIVERSITY OF VIENNA · Jul 10, 2020

Keywords

ClinConnect Summary

The EXALT-2 clinical trial is studying new treatment options for patients with aggressive blood cancers such as advanced lymphoma and leukemia that have not responded to previous therapies. This trial is designed to help doctors make better treatment decisions by using advanced techniques to understand the genetic makeup of a patient's cancer and test how their cancer responds to potential drugs. The study is currently recruiting participants aged 65 and older who have already tried at least two different treatments without success, or one treatment when no standard options are available.

To qualify for the trial, patients need to have a specific type of aggressive blood cancer, must have relapsed within six months after their last treatment, and should be able to provide consent for participation. Participants will have their cancer cells analyzed and may receive a treatment chosen based on this analysis, a drug screening test, or the doctor’s usual treatment approach. It’s important to note that patients cannot be part of another clinical trial or have certain other health conditions. If you're considering participating, this trial offers a chance to explore personalized treatment options that could be more effective for your specific cancer.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • patient is suffering from aggressive haematological disease AND has undergone at least two lines of previous therapies AND/OR has undergone at least one previous therapy and no standard treatment is available in the specific disease setting and disease specific guidelines recommend treatment in studies.
• • duration of last response is less than 6 months defined as first day of last treatment to date of relapse, the response duration has to be available with dates (dd/mm/yyyy) for initiation of and relapse to previous treatment.
• • best response to previous treatment has to be available.
• • The patient is able to give written informed consent and wishes to undergo further therapy
• • further therapy is medically feasible
• • tumor cell-containing samples can be obtained
• Exclusion Criteria:
• • current participation in another experimental clinical trial
• • performance status does not allow participation (ECOG ˃ 1)
• • pregnancy, tested at screening
• • patient suffers from classical or nodular, lymphocyte predominant Hodgkins lymphoma.
• • other malignoma, diagnosed \<1a before inclusion (except localized squamous cell carcinoma of the skin, surgically curable melanoma of the skin, basal cell carcinoma of the skin)